SEC Form 4Coverage since Aug 6, 2026
$ATTO insider trading
Over the last 12 months, Attovia Therapeutics insiders reported 4 buys totaling $25.3M and no sales across SEC Form 4 filings.
- Bought · 12m
- $25.3M 4 events
- Sold · 12m
- — 0 events
- Events · 12m
- 4 Form 4 filings, grouped
- Insiders · 12m
- 3 distinct reporters
- 10b5-1 share
- 0% pre-arranged plans
Side
Price · $ATTO · 12Mvia TradingView
Top insiders · 12m
Redmile Group, LLC—2× · $10.2M
Frazier Life Sciences XI, L.P.—1× · $10.0M
Sanofi—1× · $5.1M
All insider trades
4 events
| Date | Insider | Type | Shares | Avg price | Value | Δ stake | Marks |
|---|---|---|---|---|---|---|---|
| Aug 6, 2026 | Redmile Group, LLC10% | ▲ Buy | 400,000 | $17 | $6.8M | +51.1% | indirect |
| Aug 6, 2026 | Redmile Group, LLC10% | ▲ Buy | 200,000 | $17 | $3.4M | +25.5% | — |
| Aug 6, 2026 | Sanofi10% | ▲ Buy | 300,000 | $17 | $5.1M | +38.3% | indirect |
| Aug 6, 2026 | Frazier Life Sciences XI, L.P.10% | ▲ Buy | 588,235 | $17 | $10.0M | +10.6% | — |
About Form 4
Corporate insiders — officers, directors and 10%+ owners — must report their trades to the SEC on Form 4 within two business days. We group each filing's transactions into one economic event (a laddered 10b5-1 sale is one event, not 25 rows), flag pre-arranged plans and late filings, and link every event to its AI-scored article in the $ATTO feed.